AEON Biopharma SEC filings document its ABP-450 biosimilar program, operating and financial results, governance matters, capital structure, and NYSE American listing-status disclosures. Form 8-K reports cover material events such as financial results, Regulation FD presentations, executive appointments and compensatory arrangements, and continued-listing rule notices tied to stockholders’ equity requirements.
Proxy statements record shareholder voting procedures and meeting proposals, including capital-structure approvals tied to Class A common stock, warrants, and senior secured convertible note matters. The filings also identify AEON’s Class A common stock listed on NYSE American and describe disclosure topics common to a development-stage biopharmaceutical issuer.
AEON Biopharma, Inc. asks stockholders to authorize the Board to effect one reverse stock split of its Class A common stock at a ratio from 1-for-2 through 1-for-100, selected by the Board during the 12 months following approval and subject to the Compliance Condition; the Board may abandon the split. Approval would not itself implement a split. AEON’s prior 1-for-72 split took effect February 26, 2025, and the exchange’s cumulative-ratio limit may constrain a new ratio while that split remains within the lookback period.
If approved, amendments to the 2023 Incentive Award Plan and ESPP would include shares underlying outstanding pre-funded warrants in the fully-diluted denominator for annual increases beginning January 1, 2027, while other warrants remain excluded. The annual increase limits remain 5% for the Plan and 1% for the ESPP, subject to smaller amounts set by the Board; neither amendment adds a fixed share reserve immediately. As of October 23, 2026, 59,084,675 Common Stock shares were outstanding and entitled to one vote each. The meeting is December 15, 2026, and the Board recommends voting FOR all four proposals.
AEON Biopharma, Inc. made a corporate presentation available in the investor relations section of its website on October 23, 2026. The October 2026 presentation may also be used by management in future meetings about the company. The presentation information is furnished, not treated as filed for Section 18 liability purposes, and is not incorporated by reference into other securities filings unless specifically incorporated by reference.
AEON Biopharma, Inc. asks stockholders to approve four proposals at its December 15, 2026 special meeting: one reverse split of Common Stock at a Board-selected ratio from 1-for-2 through 1-for-100; amendments to its 2023 Incentive Award Plan and employee stock purchase plan (ESPP); and authority to adjourn. The split could occur during the 12 months after approval, subject to the Compliance Condition, and the Board may abandon it; approval alone does not effect a split.
The Plan and ESPP amendments would include shares underlying outstanding pre-funded warrants in future annual evergreen calculations, while other warrants remain excluded. Rates remain 5% for the Plan and 1% for the ESPP; the Board may set smaller increases beginning January 1, 2027. A June 30, 2026 Plan illustration gives 2,461,865 incremental shares at 5% before Board reduction, with no immediate fixed-reserve increase. Counting warrant shares does not make them voting Common Stock.
The prior 1-for-72 split constrains the ratio under the Exchange’s cumulative-ratio limit during its two-year lookback. The Board recommends “FOR” all four proposals, which are not conditioned on one another.
AEON Biopharma, Inc. said the FDA agreed in principle with its proposed two-stage comparative pharmacodynamic study design for ABP-450, using CMAP measurement in the extensor digitorum brevis muscle, and provided recommendations to strengthen assay sensitivity. AEON expects to submit an IND for the study in the fourth quarter of 2026 and plans to initiate it in the first quarter of 2027. The FDA said earlier comparative studies conducted by Daewoong Pharmaceutical may be considered as supportive evidence, subject to scientific bridging to U.S.-licensed BOTOX and between the study products and ABP-450 as currently manufactured.
AEON does not intend to initiate a standalone comparative efficacy study at this time; it plans first to evaluate its analytical, pharmacodynamic and comparative human evidence, and to return to the FDA in 2027 with an integrated evidence package. It also plans to provide analyses concerning its prior Phase 2 migraine-prevention study with its BLA submission. AEON determined that the meeting minutes satisfy the Two-Year Milestone Warrants’ contractual condition, so the warrants expire on November 16, 2026, unless exercised before then. The company said this determination is not an FDA finding of biosimilarity or that the development program or additional evidence will support approval.
AEON Biopharma, Inc. (AEON) received a Schedule 13G reporting that Timothy P. Lynch beneficially owns 6,500,000 shares of its Class A common stock. This represents 13.0% of the class, based on 49,882,790 shares outstanding as of August 6, 2026.
Lynch reports sole voting and dispositive power over all 6,500,000 shares, with no shared power. The filing notes additional prefunded warrants for 1,000,000 shares and milestone warrants for 6,000,000 shares are excluded from beneficial ownership because a 4.99% Beneficial Ownership Limitation currently prevents their exercise.
AEON Biopharma, Inc. (AEON) reported that ten percent owner Timothy P. Lynch purchased 1,150,000 shares of Class A Common Stock on August 19, 2026. The weighted average purchase price was $0.2117 per share, with individual trades ranging from $0.1975 to $0.2164. Following this open-market purchase, Lynch directly owns 6,500,000 shares of AEON Class A Common Stock.
AEON Biopharma, Inc. (AEON) disclosed the initial ownership of major shareholder Timothy P. Lynch on a Form 3. Lynch directly holds 5,350,000 shares of Class A Common Stock and derivative securities tied to additional shares. These include pre-funded warrants exercisable at $0.0001 per share for 1,000,000 underlying Class A shares that are exercisable at any time and have no expiration date.
He also holds two series of warrants, each covering 3,000,000 underlying Class A shares, with exercise prices of $0.3221 and $0.3704 per share. Certain warrants expire on the earlier of the second or fifth anniversary of issuance or 45 days after specified AEON FDA-related announcements. A 4.99% beneficial ownership limitation applies, which Lynch may adjust up to 19.99% with at least 61 days’ prior written notice, subject to the warrant terms.
AEON Biopharma, Inc. reported continued operating losses while advancing ABP-450 as a proposed biosimilar to BOTOX. For the six months ended June 30, 2026, the company recorded a net loss of $12.9 million and had an accumulated deficit of $483.8 million. Cash and cash equivalents were $3.4 million and total assets $5.9 million, against total liabilities of $21.3 million, resulting in a stockholders’ deficit of $15.4 million.
Management explicitly states there is substantial doubt about the company’s ability to continue as a going concern, given recurring losses, negative operating cash flow and limited cash. AEON is funding operations through equity and structured financings, including an at-the-market program (2.3 million shares for $2.6 million in the first half of 2026), a $6.0 million PIPE, the exchange of $15.0 million of Daewoong convertible notes into equity, a new $1.5 million senior secured convertible note, and approximately $13.6 million of net proceeds from a July 2026 offering.
AEON progressed its ABP-450 biosimilar program, holding FDA biosimilar meetings, commencing analytical studies, and planning to complete most analytical comparability work in 2026. However, future development, regulatory approval and commercialization remain dependent on securing additional capital under uncertain market and financing conditions.
AEON Biopharma, Inc. reported second quarter 2026 results and a corporate update focused on advancing ABP-450, its proposed biosimilar to BOTOX for therapeutic indications. The company highlighted FDA-regulatory progress, including a Biosimilar Biological Product Development (BPD) Type 2a meeting where the FDA reviewed its analytical similarity strategy under the 351(k) biosimilar pathway and provided feedback that supports AEON’s planned analytical development approach.
AEON completed a $15.3 million underwritten public financing in July 2026, generating approximately $13.6 million in net upfront proceeds and milestone warrants that could provide up to an additional $34.0 million in gross proceeds upon full cash exercise. The company reported cash and cash equivalents of $3.4 million as of June 30, 2026, and expects, including the July proceeds, to fund operations into the first quarter of 2027.
For the quarter ended June 30, 2026, AEON recorded a loss from operations of $5.9 million and a net loss of $1.2 million, with results influenced by non-cash fair value changes in convertible notes and warrant liabilities. Total liabilities were $21.3 million and stockholders’ deficit was $15.4 million as of June 30, 2026. The company also disclosed that it regained full NYSE American continued listing compliance on August 3, 2026.
AEON Biopharma, Inc. reports that it has regained compliance with NYSE American’s continued listing standards. NYSE Regulation confirmed that previously identified deficiencies under Sections 1003(a)(i) and 1003(a)(ii) of the NYSE American Company Guide have been resolved, so the “.BC” below-compliance indicator is expected to be removed and the company taken off NYSE American’s noncompliant issuers list, while it remains subject to ongoing listing standards.
The company regained compliance following completion of an underwritten public offering closed on July 15, 2026, involving 17,851,599 shares of Class A common stock and pre-funded warrants to purchase 24,837,008 shares, plus an additional 4,696,102 shares sold on July 23, 2026 through a partial over-allotment exercise. AEON received approximately $13.6 million in net proceeds and has the potential to receive up to $34.0 million in additional gross proceeds upon full cash exercise of milestone warrants. AEON believes its stockholders’ equity now exceeds the $4.0 million minimum required under Section 1003(a)(ii), although its June 30, 2026 balance sheet in the upcoming Form 10-Q will still show a stockholders’ deficit and reflect the offering as a subsequent event.